AstraZeneca (AZN) European Society for Medical Oncology Congress (ESMO) 2024 summary

Strategic vision and growth outlook

• Ambition to reach $80 billion in revenue by 2030, with continued growth beyond patent expiries through investment in new technologies and platforms.

• Focus on oncology, aiming to cure cancer by combining and sequencing therapies, and expanding into earlier diagnosis and smarter, targeted treatments.

• Investments in ADCs, radioconjugates, cell therapy, and T-cell engagers are expected to drive post-2030 growth.

• Minimal impact from patent expiries before 2030, with strong growth expected from existing products and new molecular entities.

• 17 positive late-stage readouts since last year, supporting confidence in the pipeline.

Key clinical data and product updates

• Presented over 130 abstracts at ESMO and World Lung, including five presidential plenary presentations.

• Highlighted positive data for Dato-DXd, Imfinzi, and next-generation IO agents, with robust efficacy and safety profiles.

• TROPION-Lung01 showed clinically meaningful PFS and OS benefit in non-squamous NSCLC, with ongoing regulatory review and biomarker-driven strategy.

• QCS biomarker technology enables precise patient selection for ADCs, with validation ongoing in first-line studies.

• Five first-line Dato-DXd NSCLC trials ongoing, targeting a >$5 billion peak revenue opportunity.

NIAGARA study and bladder cancer advances

• NIAGARA trial demonstrated significant event-free and overall survival benefit for perioperative Imfinzi in muscle-invasive bladder cancer.

• Study included a broad, real-world patient population, expanding eligibility by lowering creatinine clearance threshold.

• Results establish perioperative Imfinzi as a new standard of care, with robust safety and no new surgical risks.

• Commercial execution plans in place, with a $1 billion+ opportunity anticipated from NIAGARA and VOLGA studies.

• Regulatory path for NIAGARA considered strong due to OS benefit and unique setting compared to other perioperative trials.